The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
ARDS and the hemolytic-uremic syndrome (HUS)
Publications
Moya-Horno I, Querol Niñerola R, Bonfill Abella T, Dalmau Pórtulas E, Gallardo-Díaz E, Saigí Grau E, Pericay Pijaume C
Haemolytic uraemic syndrome associated with gemcitabine.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2010 May;12;381-3 — 2010 May — 381-3
Haemolytic uraemic syndrome: an overview.
Nephrology (Carlton, Vic.) 2006 Jun;11;213-8 — 2006 Jun — 213-8